Ultrasound screening for cholangiocarcinoma could detect premalignant lesions and early-stage diseases with survival benefits: a population-based prospective study of 4,225 subjects in an endemic area

Background Thailand has a high incidence of cholangiocarcinoma (CCA), particularly in the north and northeastern regions. Most CCA patients come at a late, unresectable stage and presently no optimal screening test for CCA has been established. We determined the prevalence of CCA in a remote norther...

Full description

Saved in:
Bibliographic Details
Published inBMC cancer Vol. 16; no. 1; p. 346
Main Authors Sungkasubun, Prakongboon, Siripongsakun, Surachate, Akkarachinorate, Kunlayanee, Vidhyarkorn, Sirachat, Worakitsitisatorn, Akeanong, Sricharunrat, Thaniya, Singharuksa, Sutida, Chanwat, Rawisak, Bunchaliew, Chairat, Charoenphattharaphesat, Sirima, Molek, Ruechuta, Yimyaem, Maneenop, Sornsamdang, Gaidganok, Soonklang, Kamonwan, Wittayasak, Kasiruck, Auewarakul, Chirayu U., Mahidol, Chulabhorn
Format Journal Article
LanguageEnglish
Published London BioMed Central 02.06.2016
BioMed Central Ltd
Subjects
Online AccessGet full text
ISSN1471-2407
1471-2407
DOI10.1186/s12885-016-2390-2

Cover

Abstract Background Thailand has a high incidence of cholangiocarcinoma (CCA), particularly in the north and northeastern regions. Most CCA patients come at a late, unresectable stage and presently no optimal screening test for CCA has been established. We determined the prevalence of CCA in a remote northern village and explored if screening could lead to early detection and survival benefits. Methods A 5-year population-based study was started in October, 2011 for consented Thai individuals, aged 30–60 years. The screening program comprised blood testing, stool examination and serial ultrasonography every 6 months. Results During the first 3 years, 4,225 eligible individuals were enrolled. CCA was detected in 32 patients, with a mean age of 51.9 years (41–62 years), and 21/32 cases were at a curative resectable stage. The prevalence rate of CCA was 165.7 per 100,000 and one- and two-year incidence rate was 236.7/100,000 and 520.7/100,000, respectively. One- and 2-year overall survival rates of CCA patients were 90.9 and 61.5 %, respectively. Prognosis was better in resectable cases with 100 % 1-year and 77.8 % 2-year survival rates. Interestingly, premalignant pathological lesions (stage 0) were identified in 11 cases with 100 % 3-year survival rate. Serum biomarkers and alkaline phosphatase were not sufficient to detect early-stage disease. In 22 patients, stool samples were positive for Opisthorchis viverrini , based on polymerase chain reaction. Conclusion Detection of premalignant lesions and early-stage resectable CCA by ultrasonography resulted in improved clinical outcome. Ultrasonography should be offered as a first screening tool for CCA in an endemic area until other useful biological markers become available.
AbstractList Background Thailand has a high incidence of cholangiocarcinoma (CCA), particularly in the north and northeastern regions. Most CCA patients come at a late, unresectable stage and presently no optimal screening test for CCA has been established. We determined the prevalence of CCA in a remote northern village and explored if screening could lead to early detection and survival benefits. Methods A 5-year population-based study was started in October, 2011 for consented Thai individuals, aged 30-60 years. The screening program comprised blood testing, stool examination and serial ultrasonography every 6 months. Results During the first 3 years, 4,225 eligible individuals were enrolled. CCA was detected in 32 patients, with a mean age of 51.9 years (41-62 years), and 21/32 cases were at a curative resectable stage. The prevalence rate of CCA was 165.7 per 100,000 and one- and two-year incidence rate was 236.7/100,000 and 520.7/100,000, respectively. One- and 2-year overall survival rates of CCA patients were 90.9 and 61.5 %, respectively. Prognosis was better in resectable cases with 100 % 1-year and 77.8 % 2-year survival rates. Interestingly, premalignant pathological lesions (stage 0) were identified in 11 cases with 100 % 3-year survival rate. Serum biomarkers and alkaline phosphatase were not sufficient to detect early-stage disease. In 22 patients, stool samples were positive for Opistorchis viverrini, based on polymerase chain reaction. Conclusion Detection of premalignant lesions and early-stage resectable CCA by ultrasonography resulted in improved clinical outcome. Ultrasonography should be offered as a first screening tool for CCA in an endemic area until other useful biological markers become available.
Background Thailand has a high incidence of cholangiocarcinoma (CCA), particularly in the north and northeastern regions. Most CCA patients come at a late, unresectable stage and presently no optimal screening test for CCA has been established. We determined the prevalence of CCA in a remote northern village and explored if screening could lead to early detection and survival benefits. Methods A 5-year population-based study was started in October, 2011 for consented Thai individuals, aged 30–60 years. The screening program comprised blood testing, stool examination and serial ultrasonography every 6 months. Results During the first 3 years, 4,225 eligible individuals were enrolled. CCA was detected in 32 patients, with a mean age of 51.9 years (41–62 years), and 21/32 cases were at a curative resectable stage. The prevalence rate of CCA was 165.7 per 100,000 and one- and two-year incidence rate was 236.7/100,000 and 520.7/100,000, respectively. One- and 2-year overall survival rates of CCA patients were 90.9 and 61.5 %, respectively. Prognosis was better in resectable cases with 100 % 1-year and 77.8 % 2-year survival rates. Interestingly, premalignant pathological lesions (stage 0) were identified in 11 cases with 100 % 3-year survival rate. Serum biomarkers and alkaline phosphatase were not sufficient to detect early-stage disease. In 22 patients, stool samples were positive for Opisthorchis viverrini , based on polymerase chain reaction. Conclusion Detection of premalignant lesions and early-stage resectable CCA by ultrasonography resulted in improved clinical outcome. Ultrasonography should be offered as a first screening tool for CCA in an endemic area until other useful biological markers become available.
Thailand has a high incidence of cholangiocarcinoma (CCA), particularly in the north and northeastern regions. Most CCA patients come at a late, unresectable stage and presently no optimal screening test for CCA has been established. We determined the prevalence of CCA in a remote northern village and explored if screening could lead to early detection and survival benefits. A 5-year population-based study was started in October, 2011 for consented Thai individuals, aged 30-60 years. The screening program comprised blood testing, stool examination and serial ultrasonography every 6 months. During the first 3 years, 4,225 eligible individuals were enrolled. CCA was detected in 32 patients, with a mean age of 51.9 years (41-62 years), and 21/32 cases were at a curative resectable stage. The prevalence rate of CCA was 165.7 per 100,000 and one- and two-year incidence rate was 236.7/100,000 and 520.7/100,000, respectively. One- and 2-year overall survival rates of CCA patients were 90.9 and 61.5 %, respectively. Prognosis was better in resectable cases with 100 % 1-year and 77.8 % 2-year survival rates. Interestingly, premalignant pathological lesions (stage 0) were identified in 11 cases with 100 % 3-year survival rate. Serum biomarkers and alkaline phosphatase were not sufficient to detect early-stage disease. In 22 patients, stool samples were positive for Opistorchis viverrini, based on polymerase chain reaction. Detection of premalignant lesions and early-stage resectable CCA by ultrasonography resulted in improved clinical outcome. Ultrasonography should be offered as a first screening tool for CCA in an endemic area until other useful biological markers become available.
Background Thailand has a high incidence of cholangiocarcinoma (CCA), particularly in the north and northeastern regions. Most CCA patients come at a late, unresectable stage and presently no optimal screening test for CCA has been established. We determined the prevalence of CCA in a remote northern village and explored if screening could lead to early detection and survival benefits. Methods A 5-year population-based study was started in October, 2011 for consented Thai individuals, aged 30-60 years. The screening program comprised blood testing, stool examination and serial ultrasonography every 6 months. Results During the first 3 years, 4,225 eligible individuals were enrolled. CCA was detected in 32 patients, with a mean age of 51.9 years (41-62 years), and 21/32 cases were at a curative resectable stage. The prevalence rate of CCA was 165.7 per 100,000 and one- and two-year incidence rate was 236.7/100,000 and 520.7/100,000, respectively. One- and 2-year overall survival rates of CCA patients were 90.9 and 61.5 %, respectively. Prognosis was better in resectable cases with 100 % 1-year and 77.8 % 2-year survival rates. Interestingly, premalignant pathological lesions (stage 0) were identified in 11 cases with 100 % 3-year survival rate. Serum biomarkers and alkaline phosphatase were not sufficient to detect early-stage disease. In 22 patients, stool samples were positive for Opistorchis viverrini, based on polymerase chain reaction. Conclusion Detection of premalignant lesions and early-stage resectable CCA by ultrasonography resulted in improved clinical outcome. Ultrasonography should be offered as a first screening tool for CCA in an endemic area until other useful biological markers become available. Keywords: Cholangiocarcinoma, Premalignant lesions, Cancer screening, Early detection, Ultrasonography, Tumor markers
Thailand has a high incidence of cholangiocarcinoma (CCA), particularly in the north and northeastern regions. Most CCA patients come at a late, unresectable stage and presently no optimal screening test for CCA has been established. We determined the prevalence of CCA in a remote northern village and explored if screening could lead to early detection and survival benefits. A 5-year population-based study was started in October, 2011 for consented Thai individuals, aged 30-60 years. The screening program comprised blood testing, stool examination and serial ultrasonography every 6 months. During the first 3 years, 4,225 eligible individuals were enrolled. CCA was detected in 32 patients, with a mean age of 51.9 years (41-62 years), and 21/32 cases were at a curative resectable stage. The prevalence rate of CCA was 165.7 per 100,000 and one- and two-year incidence rate was 236.7/100,000 and 520.7/100,000, respectively. One- and 2-year overall survival rates of CCA patients were 90.9 and 61.5 %, respectively. Prognosis was better in resectable cases with 100 % 1-year and 77.8 % 2-year survival rates. Interestingly, premalignant pathological lesions (stage 0) were identified in 11 cases with 100 % 3-year survival rate. Serum biomarkers and alkaline phosphatase were not sufficient to detect early-stage disease. In 22 patients, stool samples were positive for Opistorchis viverrini, based on polymerase chain reaction. Detection of premalignant lesions and early-stage resectable CCA by ultrasonography resulted in improved clinical outcome. Ultrasonography should be offered as a first screening tool for CCA in an endemic area until other useful biological markers become available.
Thailand has a high incidence of cholangiocarcinoma (CCA), particularly in the north and northeastern regions. Most CCA patients come at a late, unresectable stage and presently no optimal screening test for CCA has been established. We determined the prevalence of CCA in a remote northern village and explored if screening could lead to early detection and survival benefits.BACKGROUNDThailand has a high incidence of cholangiocarcinoma (CCA), particularly in the north and northeastern regions. Most CCA patients come at a late, unresectable stage and presently no optimal screening test for CCA has been established. We determined the prevalence of CCA in a remote northern village and explored if screening could lead to early detection and survival benefits.A 5-year population-based study was started in October, 2011 for consented Thai individuals, aged 30-60 years. The screening program comprised blood testing, stool examination and serial ultrasonography every 6 months.METHODSA 5-year population-based study was started in October, 2011 for consented Thai individuals, aged 30-60 years. The screening program comprised blood testing, stool examination and serial ultrasonography every 6 months.During the first 3 years, 4,225 eligible individuals were enrolled. CCA was detected in 32 patients, with a mean age of 51.9 years (41-62 years), and 21/32 cases were at a curative resectable stage. The prevalence rate of CCA was 165.7 per 100,000 and one- and two-year incidence rate was 236.7/100,000 and 520.7/100,000, respectively. One- and 2-year overall survival rates of CCA patients were 90.9 and 61.5 %, respectively. Prognosis was better in resectable cases with 100 % 1-year and 77.8 % 2-year survival rates. Interestingly, premalignant pathological lesions (stage 0) were identified in 11 cases with 100 % 3-year survival rate. Serum biomarkers and alkaline phosphatase were not sufficient to detect early-stage disease. In 22 patients, stool samples were positive for Opistorchis viverrini, based on polymerase chain reaction.RESULTSDuring the first 3 years, 4,225 eligible individuals were enrolled. CCA was detected in 32 patients, with a mean age of 51.9 years (41-62 years), and 21/32 cases were at a curative resectable stage. The prevalence rate of CCA was 165.7 per 100,000 and one- and two-year incidence rate was 236.7/100,000 and 520.7/100,000, respectively. One- and 2-year overall survival rates of CCA patients were 90.9 and 61.5 %, respectively. Prognosis was better in resectable cases with 100 % 1-year and 77.8 % 2-year survival rates. Interestingly, premalignant pathological lesions (stage 0) were identified in 11 cases with 100 % 3-year survival rate. Serum biomarkers and alkaline phosphatase were not sufficient to detect early-stage disease. In 22 patients, stool samples were positive for Opistorchis viverrini, based on polymerase chain reaction.Detection of premalignant lesions and early-stage resectable CCA by ultrasonography resulted in improved clinical outcome. Ultrasonography should be offered as a first screening tool for CCA in an endemic area until other useful biological markers become available.CONCLUSIONDetection of premalignant lesions and early-stage resectable CCA by ultrasonography resulted in improved clinical outcome. Ultrasonography should be offered as a first screening tool for CCA in an endemic area until other useful biological markers become available.
ArticleNumber 346
Audience Academic
Author Worakitsitisatorn, Akeanong
Yimyaem, Maneenop
Siripongsakun, Surachate
Chanwat, Rawisak
Wittayasak, Kasiruck
Sungkasubun, Prakongboon
Singharuksa, Sutida
Auewarakul, Chirayu U.
Soonklang, Kamonwan
Vidhyarkorn, Sirachat
Bunchaliew, Chairat
Sricharunrat, Thaniya
Mahidol, Chulabhorn
Charoenphattharaphesat, Sirima
Akkarachinorate, Kunlayanee
Sornsamdang, Gaidganok
Molek, Ruechuta
Author_xml – sequence: 1
  givenname: Prakongboon
  surname: Sungkasubun
  fullname: Sungkasubun, Prakongboon
  organization: Chulabhorn Hospital
– sequence: 2
  givenname: Surachate
  surname: Siripongsakun
  fullname: Siripongsakun, Surachate
  organization: Chulabhorn Hospital
– sequence: 3
  givenname: Kunlayanee
  surname: Akkarachinorate
  fullname: Akkarachinorate, Kunlayanee
  organization: Ban Luang Hospital
– sequence: 4
  givenname: Sirachat
  surname: Vidhyarkorn
  fullname: Vidhyarkorn, Sirachat
  organization: Chulabhorn Hospital
– sequence: 5
  givenname: Akeanong
  surname: Worakitsitisatorn
  fullname: Worakitsitisatorn, Akeanong
  organization: Chulabhorn Hospital
– sequence: 6
  givenname: Thaniya
  surname: Sricharunrat
  fullname: Sricharunrat, Thaniya
  organization: Chulabhorn Hospital
– sequence: 7
  givenname: Sutida
  surname: Singharuksa
  fullname: Singharuksa, Sutida
  organization: Chulabhorn Hospital
– sequence: 8
  givenname: Rawisak
  surname: Chanwat
  fullname: Chanwat, Rawisak
  organization: National Cancer Institute of Thailand
– sequence: 9
  givenname: Chairat
  surname: Bunchaliew
  fullname: Bunchaliew, Chairat
  organization: National Cancer Institute of Thailand
– sequence: 10
  givenname: Sirima
  surname: Charoenphattharaphesat
  fullname: Charoenphattharaphesat, Sirima
  organization: Chulabhorn Hospital
– sequence: 11
  givenname: Ruechuta
  surname: Molek
  fullname: Molek, Ruechuta
  organization: Chulabhorn Hospital
– sequence: 12
  givenname: Maneenop
  surname: Yimyaem
  fullname: Yimyaem, Maneenop
  organization: Chulabhorn Hospital
– sequence: 13
  givenname: Gaidganok
  surname: Sornsamdang
  fullname: Sornsamdang, Gaidganok
  organization: Chulabhorn Hospital
– sequence: 14
  givenname: Kamonwan
  surname: Soonklang
  fullname: Soonklang, Kamonwan
  organization: Chulabhorn Hospital
– sequence: 15
  givenname: Kasiruck
  surname: Wittayasak
  fullname: Wittayasak, Kasiruck
  organization: Chulabhorn Hospital
– sequence: 16
  givenname: Chirayu U.
  surname: Auewarakul
  fullname: Auewarakul, Chirayu U.
  organization: Chulabhorn Hospital, Faculty of Medicine Siriraj Hospital, Mahidol University
– sequence: 17
  givenname: Chulabhorn
  surname: Mahidol
  fullname: Mahidol, Chulabhorn
  email: cmah2500@gmail.com
  organization: Chulabhorn Hospital, Faculty of Medicine Siriraj Hospital, Mahidol University, Chulabhorn Research Institute
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27251649$$D View this record in MEDLINE/PubMed
BookMark eNqNkm1r1EAUhYNUbLv6A_wiA4IomDozm1c_CKX4UigIaj8Pd2duslNmZ9KZydb9h_4sZ7ur3S0qEkhC8pxzk3PucXZgncUse8roCWNN9SYw3jRlTlmV82lLc_4gO2JFzXJe0Ppg5_4wOw7hilJWN7R5lB3ympesKtqj7MeliR6CG60iQXpEq21POueJnDsDttdOgpfaugUQ6UajiMKIMpLB4wKM7i3YSAwG7WwgkGwQvFnlIUKPROmAEDCQGx3nJIx-qZdgyAwtdjqGtwTI4IbRQEzyfJZQlYxdGNIEvUQS4qhWxHWkeM15mQxmV-lNINqmUQStwoWWBDzC4-xhBybgk-11kl1-eP_t7FN-8fnj-dnpRS4rymMOCmZMVl3XYKF4VUyhqKFE3nDGlZLIgLaqhGrGq5Y2qpAMZIuyZdOCVp2C6STjG9_RDrC6AWPE4PUC_EowKta1iE0tItUi1rWk0yR7txEN42yBaYxNod8JHWix_8bquejdUhRNS0vWJoOXWwPvrkcMUSx0kGhSQ-jGIFjdTlvGWFsm9Pk99MqN3qZMBGsorRmdsuqO6sGg0LZzaa5cm4rTomqatmHl-rtP_kCl4zZ3ty4xPd8TvNoTJCbi99jDGII4__pln32xw84RTJwHZ8b1KoR98Nluer9j-7XFCWAbQKbVCR67_6qkvqeROt6uYfpFbf6p3G5ASFNsj34n4L-KfgJKXShw
CitedBy_id crossref_primary_10_1111_jog_13402
crossref_primary_10_3233_CBM_210170
crossref_primary_10_1016_j_jcjd_2020_09_008
crossref_primary_10_1016_j_parint_2016_11_011
crossref_primary_10_1016_j_parepi_2024_e00391
crossref_primary_10_4103_jcrt_JCRT_1703_20
crossref_primary_10_3389_fmed_2022_893252
crossref_primary_10_1038_s41598_022_17794_9
crossref_primary_10_1016_j_jhep_2023_03_010
crossref_primary_10_1007_s00261_019_01951_2
crossref_primary_10_3390_pathogens9110971
crossref_primary_10_1016_j_gtc_2018_01_002
crossref_primary_10_1016_j_hpb_2022_06_004
crossref_primary_10_1016_j_livres_2022_09_001
crossref_primary_10_1016_j_hpb_2019_10_010
crossref_primary_10_1111_jgh_14074
crossref_primary_10_1016_j_parint_2016_12_005
crossref_primary_10_1016_j_heliyon_2024_e38191
crossref_primary_10_1371_journal_pone_0246490
crossref_primary_10_1016_j_cmpb_2021_106265
crossref_primary_10_1186_s12885_021_08247_z
crossref_primary_10_1038_srep42744
crossref_primary_10_3390_ijms21030814
crossref_primary_10_7759_cureus_62531
crossref_primary_10_3347_kjp_2017_55_3_295
crossref_primary_10_1007_s10396_024_01491_3
Cites_doi 10.1016/0035-9203(91)90055-4
10.3322/caac.20107
10.1016/j.trecan.2015.08.011
10.1038/ncomms5378
10.1007/s005340050177
10.1046/j.1365-2168.2002.02143.x
10.1016/j.jhep.2006.09.001
10.1007/s005340050095
10.1038/sj.bjc.6603127
10.14218/JCTH.2015.00012
10.1200/JCO.2005.05.2308
10.1158/1055-9965.EPI-05-0811
10.1371/journal.pmed.0040201
10.7314/APJCP.2012.14.11.7029
10.1002/jhbp.63
10.1007/s00432-010-0971-z
10.1001/jama.2010.1525
10.1016/S0168-8278(02)00297-0
10.1097/MOG.0b013e3282fbf9b3
10.1038/ng.2273
10.3748/wjg.v18.i5.458
10.1158/1538-7445.AM2015-LB-173
10.1002/jhbp.74
10.1111/j.1349-7006.2009.01458.x
10.1053/jhep.2001.25087
10.1093/jnci/djj234
10.1016/j.cld.2007.11.003
10.1016/j.parint.2011.06.007
10.1055/s-0034-1394144
10.3748/wjg.14.6458
10.1097/SLA.0b013e318176c4d3
10.1002/cncr.28312
ContentType Journal Article
Copyright The Author(s). 2016
COPYRIGHT 2016 BioMed Central Ltd.
Copyright BioMed Central 2016
Copyright_xml – notice: The Author(s). 2016
– notice: COPYRIGHT 2016 BioMed Central Ltd.
– notice: Copyright BioMed Central 2016
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
ISR
3V.
7TO
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
7X8
5PM
ADTOC
UNPAY
DOI 10.1186/s12885-016-2390-2
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Gale In Context: Science
ProQuest Central (Corporate)
Oncogenes and Growth Factors Abstracts
Health & Medical Collection (ProQuest)
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni Edition)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
MEDLINE - Academic
PubMed Central (Full Participant titles)
Unpaywall for CDI: Periodical Content
Unpaywall
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database

MEDLINE


MEDLINE - Academic


Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
– sequence: 5
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1471-2407
ExternalDocumentID 10.1186/s12885-016-2390-2
PMC4890519
4105387541
A468898152
27251649
10_1186_s12885_016_2390_2
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Thailand
GeographicLocations_xml – name: Thailand
GrantInformation_xml – fundername: Chulabhorn Hospital
– fundername: ;
GroupedDBID ---
0R~
23N
2WC
4.4
53G
5VS
6J9
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACMJI
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHSBF
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EJD
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
H13
HMCUK
HYE
IAO
IHR
IHW
INH
INR
ISR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
PUEGO
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
SV3
TR2
TUS
U2A
UKHRP
W2D
WOQ
WOW
XSB
AAYXX
CITATION
-A0
3V.
ACRMQ
ADINQ
ALIPV
C24
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
7TO
7XB
8FK
AZQEC
DWQXO
H94
K9.
PKEHL
PQEST
PQUKI
7X8
5PM
2VQ
ADTOC
C1A
IPNFZ
LGEZI
LOTEE
NADUK
NXXTH
RIG
UNPAY
ID FETCH-LOGICAL-c602t-adab1c6ff8e4d2643a47a5e28212ddce1a09d5a6b26908d4c1ac9ec913406fda3
IEDL.DBID M48
ISSN 1471-2407
IngestDate Wed Oct 01 16:04:31 EDT 2025
Tue Sep 30 16:57:04 EDT 2025
Fri Sep 05 10:27:58 EDT 2025
Fri Jul 25 02:00:51 EDT 2025
Tue Jun 17 22:05:39 EDT 2025
Tue Jun 10 21:04:41 EDT 2025
Fri Jun 27 05:47:25 EDT 2025
Thu May 22 21:24:15 EDT 2025
Thu Jan 02 22:25:10 EST 2025
Wed Oct 01 03:44:32 EDT 2025
Thu Apr 24 23:00:58 EDT 2025
Sat Sep 06 07:24:36 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Tumor markers
Premalignant lesions
Cholangiocarcinoma
Early detection
Ultrasonography
Cancer screening
Language English
License Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
cc-by
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c602t-adab1c6ff8e4d2643a47a5e28212ddce1a09d5a6b26908d4c1ac9ec913406fda3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12885-016-2390-2
PMID 27251649
PQID 1800710316
PQPubID 44074
ParticipantIDs unpaywall_primary_10_1186_s12885_016_2390_2
pubmedcentral_primary_oai_pubmedcentral_nih_gov_4890519
proquest_miscellaneous_1793911195
proquest_journals_1800710316
gale_infotracmisc_A468898152
gale_infotracacademiconefile_A468898152
gale_incontextgauss_ISR_A468898152
gale_healthsolutions_A468898152
pubmed_primary_27251649
crossref_primary_10_1186_s12885_016_2390_2
crossref_citationtrail_10_1186_s12885_016_2390_2
springer_journals_10_1186_s12885_016_2390_2
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2016-06-02
PublicationDateYYYYMMDD 2016-06-02
PublicationDate_xml – month: 06
  year: 2016
  text: 2016-06-02
  day: 02
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle BMC cancer
PublicationTitleAbbrev BMC Cancer
PublicationTitleAlternate BMC Cancer
PublicationYear 2016
Publisher BioMed Central
BioMed Central Ltd
Publisher_xml – name: BioMed Central
– name: BioMed Central Ltd
References T Patel (2390_CR2) 2001; 33
T Nitta (2390_CR26) 2015; 8
Y Ustundag (2390_CR1) 2008; 14
J West (2390_CR3) 2006; 94
2390_CR27
M Sato (2390_CR35) 2010; 41
2390_CR23
2390_CR22
2390_CR21
2390_CR20
I Endo (2390_CR12) 2008; 248
JS Chang (2390_CR29) 2013; 8
N Thunyaharn (2390_CR9) 2013; 14
J Chaisaingmongkol (2390_CR40) 2015; 75
N Khuntikeo (2390_CR11) 2014; 21
ND Young (2390_CR33) 2014; 5
G Kabbach (2390_CR41) 2015; 3
V Vatanasapt (2390_CR17) 1993
B Sripa (2390_CR31) 2007; 4
CK Ong (2390_CR39) 2012; 44
HR Shin (2390_CR14) 2010; 101
AR Yusoff (2390_CR25) 2012; 18
P Watanapa (2390_CR32) 2002; 89
TM Welzel (2390_CR5) 2006; 98
H Suzuki (2390_CR28) 2000; 7
B Sripa (2390_CR19) 2008; 24
T Uttaravichien (2390_CR10) 1999; 6
SK Maithel (2390_CR24) 2013; 119
BR Blechacz (2390_CR8) 2008; 12
AK Singal (2390_CR30) 2011; 137
ST Hong (2390_CR34) 2012; 61
P Yongvanit (2390_CR38) 2014; 21
F Kamangar (2390_CR15) 2006; 24
S Rizvi (2390_CR42) 2014; 34
S Pungpak (2390_CR37) 1991; 85
F Mihalache (2390_CR13) 2010; 19
KA McGlynn (2390_CR6) 2006; 15
A Jemal (2390_CR16) 2011; 61
M Carpelan-Holmström (2390_CR36) 2001; 22
H Malhi (2390_CR7) 2006; 45
PJ Brindley (2390_CR18) 2015; 1
SA Khan (2390_CR4) 2002; 37
20085587 - Cancer Sci. 2010 Mar;101(3):579-85
26618199 - Trends Cancer. 2015 Nov 1;1(3):174-182
19030196 - World J Gastroenterol. 2008 Nov 14;14(42):6458-66
10398899 - J Hepatobiliary Pancreat Surg. 1999;6(2):128-35
21296855 - CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
23963845 - Cancer. 2013 Nov 15;119(22):3929-42
24408859 - J Hepatobiliary Pancreat Sci. 2014 May;21(5):309-15
26623263 - J Clin Transl Hepatol. 2015 Sep 28;3(3):169-81
21741496 - Parasitol Int. 2012 Mar;61(1):17-24
16788161 - J Natl Cancer Inst. 2006 Jun 21;98(12):873-5
16736026 - Br J Cancer. 2006 Jun 5;94(11):1751-8
1653472 - Trans R Soc Trop Med Hyg. 1991 Mar-Apr;85(2):277-9
12174919 - Anticancer Res. 2002 Jul-Aug;22(4):2311-6
17622191 - PLoS Med. 2007 Jul;4(7):e201
26339398 - Int J Clin Exp Pathol. 2015 Jul 01;8(7):8284-90
20578479 - Southeast Asian J Trop Med Public Health. 2010 Jan;41(1):28-35
16775181 - Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1198-203
16682732 - J Clin Oncol. 2006 May 10;24(14):2137-50
12153620 - Br J Surg. 2002 Aug;89(8):962-70
18580211 - Ann Surg. 2008 Jul;248(1):84-96
21207060 - J Cancer Res Clin Oncol. 2011 Jul;137(7):1071-8
20922193 - J Gastrointestin Liver Dis. 2010 Sep;19(3):285-90
25007141 - Nat Commun. 2014 Jul 09;5:4378
24464976 - J Hepatobiliary Pancreat Sci. 2014 Aug;21(8):521-4
12445422 - J Hepatol. 2002 Dec;37(6):806-13
17030071 - J Hepatol. 2006 Dec;45(6):856-67
22561520 - Nat Genet. 2012 May 06;44(6):690-3
18242501 - Clin Liver Dis. 2008 Feb;12(1):131-50, ix
22346252 - World J Gastroenterol. 2012 Feb 7;18(5):458-65
23894567 - PLoS One. 2013 Jul 22;8(7):e69981
10982615 - J Hepatobiliary Pancreat Surg. 2000;7(2):206-11
25369307 - Semin Liver Dis. 2014 Nov;34(4):456-64
18408464 - Curr Opin Gastroenterol. 2008 May;24(3):349-56
11391522 - Hepatology. 2001 Jun;33(6):1353-7
24377644 - Asian Pac J Cancer Prev. 2013;14(11):7029-32
References_xml – volume: 22
  start-page: 2311
  issue: 4
  year: 2001
  ident: 2390_CR36
  publication-title: Anticancer Res
– volume: 85
  start-page: 277
  issue: 2
  year: 1991
  ident: 2390_CR37
  publication-title: Trans R Soc Trop Med Hyg
  doi: 10.1016/0035-9203(91)90055-4
– volume: 61
  start-page: 69
  issue: 2
  year: 2011
  ident: 2390_CR16
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.20107
– volume: 1
  start-page: 174
  issue: 3
  year: 2015
  ident: 2390_CR18
  publication-title: Trends Cancer
  doi: 10.1016/j.trecan.2015.08.011
– volume: 5
  start-page: 4378
  year: 2014
  ident: 2390_CR33
  publication-title: Nat Commun
  doi: 10.1038/ncomms5378
– volume: 7
  start-page: 206
  issue: 2
  year: 2000
  ident: 2390_CR28
  publication-title: J Hepatobiliary Pancreat Surg
  doi: 10.1007/s005340050177
– start-page: 88
  volume-title: Cancer in Thailand 1988–1991 (No. 16)
  year: 1993
  ident: 2390_CR17
– ident: 2390_CR20
– volume: 89
  start-page: 962
  issue: 8
  year: 2002
  ident: 2390_CR32
  publication-title: Br J Surg
  doi: 10.1046/j.1365-2168.2002.02143.x
– volume: 45
  start-page: 856
  issue: 6
  year: 2006
  ident: 2390_CR7
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2006.09.001
– volume: 8
  start-page: 8284
  issue: 7
  year: 2015
  ident: 2390_CR26
  publication-title: Int J Clin Exp Pathol
– volume: 6
  start-page: 128
  issue: 2
  year: 1999
  ident: 2390_CR10
  publication-title: J Hepatobiliary Pancreat Surg
  doi: 10.1007/s005340050095
– volume: 8
  issue: 7
  year: 2013
  ident: 2390_CR29
  publication-title: PLoS One
– ident: 2390_CR23
– volume: 94
  start-page: 1751
  issue: 11
  year: 2006
  ident: 2390_CR3
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6603127
– ident: 2390_CR27
– volume: 3
  start-page: 169
  issue: 3
  year: 2015
  ident: 2390_CR41
  publication-title: J Clin Transl Hepatol
  doi: 10.14218/JCTH.2015.00012
– volume: 24
  start-page: 2137
  issue: 14
  year: 2006
  ident: 2390_CR15
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.05.2308
– volume: 15
  start-page: 1198
  issue: 6
  year: 2006
  ident: 2390_CR6
  publication-title: Cancer Epidemiol Biomarkers Prev
  doi: 10.1158/1055-9965.EPI-05-0811
– volume: 4
  issue: 7
  year: 2007
  ident: 2390_CR31
  publication-title: PLoS Med
  doi: 10.1371/journal.pmed.0040201
– volume: 14
  start-page: 7029
  issue: 11
  year: 2013
  ident: 2390_CR9
  publication-title: Asian Pac J Cancer Prev
  doi: 10.7314/APJCP.2012.14.11.7029
– volume: 21
  start-page: 309
  issue: 5
  year: 2014
  ident: 2390_CR38
  publication-title: J Hepatobiliary Pancreat Sci
  doi: 10.1002/jhbp.63
– volume: 19
  start-page: 285
  issue: 3
  year: 2010
  ident: 2390_CR13
  publication-title: J Gastrointestin Liver Dis
– volume: 41
  start-page: 28
  issue: 1
  year: 2010
  ident: 2390_CR35
  publication-title: Southeast Asian J Trop Med Public Health
– volume: 137
  start-page: 1071
  issue: 7
  year: 2011
  ident: 2390_CR30
  publication-title: J Cancer Res Clin Oncol
  doi: 10.1007/s00432-010-0971-z
– ident: 2390_CR22
  doi: 10.1001/jama.2010.1525
– volume: 37
  start-page: 806
  issue: 6
  year: 2002
  ident: 2390_CR4
  publication-title: J Hepatol
  doi: 10.1016/S0168-8278(02)00297-0
– volume: 24
  start-page: 349
  issue: 3
  year: 2008
  ident: 2390_CR19
  publication-title: Curr Opin Gastroenterol
  doi: 10.1097/MOG.0b013e3282fbf9b3
– volume: 44
  start-page: 690
  issue: 6
  year: 2012
  ident: 2390_CR39
  publication-title: Nat Genet
  doi: 10.1038/ng.2273
– ident: 2390_CR21
– volume: 18
  start-page: 458
  issue: 5
  year: 2012
  ident: 2390_CR25
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v18.i5.458
– volume: 75
  start-page: LB-173
  issue: 15 Supplement
  year: 2015
  ident: 2390_CR40
  publication-title: Cancer Res
  doi: 10.1158/1538-7445.AM2015-LB-173
– volume: 21
  start-page: 521
  issue: 8
  year: 2014
  ident: 2390_CR11
  publication-title: J Hepatobiliary Pancreat Sci
  doi: 10.1002/jhbp.74
– volume: 101
  start-page: 579
  issue: 3
  year: 2010
  ident: 2390_CR14
  publication-title: Cancer Sci
  doi: 10.1111/j.1349-7006.2009.01458.x
– volume: 33
  start-page: 1353
  issue: 6
  year: 2001
  ident: 2390_CR2
  publication-title: Hepatology
  doi: 10.1053/jhep.2001.25087
– volume: 98
  start-page: 873
  issue: 12
  year: 2006
  ident: 2390_CR5
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djj234
– volume: 12
  start-page: 131
  issue: 1
  year: 2008
  ident: 2390_CR8
  publication-title: Clin Liver Dis
  doi: 10.1016/j.cld.2007.11.003
– volume: 61
  start-page: 17
  issue: 1
  year: 2012
  ident: 2390_CR34
  publication-title: Parasitol Int
  doi: 10.1016/j.parint.2011.06.007
– volume: 34
  start-page: 456
  issue: 4
  year: 2014
  ident: 2390_CR42
  publication-title: Semin Liver Dis
  doi: 10.1055/s-0034-1394144
– volume: 14
  start-page: 6458
  issue: 42
  year: 2008
  ident: 2390_CR1
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.14.6458
– volume: 248
  start-page: 84
  issue: 1
  year: 2008
  ident: 2390_CR12
  publication-title: Ann Surg
  doi: 10.1097/SLA.0b013e318176c4d3
– volume: 119
  start-page: 3929
  issue: 22
  year: 2013
  ident: 2390_CR24
  publication-title: Cancer
  doi: 10.1002/cncr.28312
– reference: 23963845 - Cancer. 2013 Nov 15;119(22):3929-42
– reference: 16736026 - Br J Cancer. 2006 Jun 5;94(11):1751-8
– reference: 23894567 - PLoS One. 2013 Jul 22;8(7):e69981
– reference: 24464976 - J Hepatobiliary Pancreat Sci. 2014 Aug;21(8):521-4
– reference: 16682732 - J Clin Oncol. 2006 May 10;24(14):2137-50
– reference: 24377644 - Asian Pac J Cancer Prev. 2013;14(11):7029-32
– reference: 16788161 - J Natl Cancer Inst. 2006 Jun 21;98(12):873-5
– reference: 18408464 - Curr Opin Gastroenterol. 2008 May;24(3):349-56
– reference: 21207060 - J Cancer Res Clin Oncol. 2011 Jul;137(7):1071-8
– reference: 17030071 - J Hepatol. 2006 Dec;45(6):856-67
– reference: 19030196 - World J Gastroenterol. 2008 Nov 14;14(42):6458-66
– reference: 1653472 - Trans R Soc Trop Med Hyg. 1991 Mar-Apr;85(2):277-9
– reference: 18242501 - Clin Liver Dis. 2008 Feb;12(1):131-50, ix
– reference: 26339398 - Int J Clin Exp Pathol. 2015 Jul 01;8(7):8284-90
– reference: 12153620 - Br J Surg. 2002 Aug;89(8):962-70
– reference: 12174919 - Anticancer Res. 2002 Jul-Aug;22(4):2311-6
– reference: 10982615 - J Hepatobiliary Pancreat Surg. 2000;7(2):206-11
– reference: 26623263 - J Clin Transl Hepatol. 2015 Sep 28;3(3):169-81
– reference: 25007141 - Nat Commun. 2014 Jul 09;5:4378
– reference: 11391522 - Hepatology. 2001 Jun;33(6):1353-7
– reference: 20922193 - J Gastrointestin Liver Dis. 2010 Sep;19(3):285-90
– reference: 12445422 - J Hepatol. 2002 Dec;37(6):806-13
– reference: 21296855 - CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
– reference: 21741496 - Parasitol Int. 2012 Mar;61(1):17-24
– reference: 16775181 - Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1198-203
– reference: 26618199 - Trends Cancer. 2015 Nov 1;1(3):174-182
– reference: 18580211 - Ann Surg. 2008 Jul;248(1):84-96
– reference: 20578479 - Southeast Asian J Trop Med Public Health. 2010 Jan;41(1):28-35
– reference: 10398899 - J Hepatobiliary Pancreat Surg. 1999;6(2):128-35
– reference: 22346252 - World J Gastroenterol. 2012 Feb 7;18(5):458-65
– reference: 17622191 - PLoS Med. 2007 Jul;4(7):e201
– reference: 24408859 - J Hepatobiliary Pancreat Sci. 2014 May;21(5):309-15
– reference: 20085587 - Cancer Sci. 2010 Mar;101(3):579-85
– reference: 22561520 - Nat Genet. 2012 May 06;44(6):690-3
– reference: 25369307 - Semin Liver Dis. 2014 Nov;34(4):456-64
SSID ssj0017808
Score 2.3352668
Snippet Background Thailand has a high incidence of cholangiocarcinoma (CCA), particularly in the north and northeastern regions. Most CCA patients come at a late,...
Thailand has a high incidence of cholangiocarcinoma (CCA), particularly in the north and northeastern regions. Most CCA patients come at a late, unresectable...
Background Thailand has a high incidence of cholangiocarcinoma (CCA), particularly in the north and northeastern regions. Most CCA patients come at a late,...
SourceID unpaywall
pubmedcentral
proquest
gale
pubmed
crossref
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 346
SubjectTerms Adult
Antigens
Bans
Bile Duct Neoplasms - diagnostic imaging
Bile Duct Neoplasms - mortality
Bile Duct Neoplasms - surgery
Bile ducts
Bile Ducts, Intrahepatic - diagnostic imaging
Biomedical and Life Sciences
Biomedicine
Cancer
Cancer Research
Cancer therapies
Cholangiocarcinoma
Cholangiocarcinoma - diagnostic imaging
Cholangiocarcinoma - mortality
Cholangiocarcinoma - surgery
Diagnosis
Disease-Free Survival
Early Detection of Cancer
Endemic Diseases
Epidemiology
Female
Health Promotion and Disease Prevention
Hepatitis
Hospitals
Humans
Liver cancer
Magnetic resonance imaging
Male
Medicine/Public Health
Middle Aged
Oncology
Phosphatase
Population
prevention and public health
Prospective Studies
Research Article
Surgical Oncology
Ultrasonic imaging
Ultrasonography
Ultrasound imaging
SummonAdditionalLinks – databaseName: Health & Medical Collection (ProQuest)
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lj9MwELZgkWA5IN4bWGBASEgs0ebhOA4XtEKsFqTlAFTqLXJsp1Rqk1K3QvxDfhYzqRualVguOTRjN4nH3zw9w9hLkddJmkU25Lmp8BIVoTJ1FuapyIvaClV05RjOP4uzEf80zsbe4eZ8WuUWEzugNq0mH_lxLDtpmMbi3eJHSF2jKLrqW2hcZddiVFWIq_Nxb3DFuYykj2TGUhw7xGJJqWoiTNDUD5OBLLqIyDsi6WK6ZB8zvclurJuF-vVTzWY7Yun0Nrvl9Uk42TDAHXbFNnfZ9XMfMb_Hfo9mOJuj5kmACIFWK04JqKlCZ9U2kykKsyXStnMFmvpdg7EUWIDF0s5RSZ9QpgzMLHnVHCicxlJN5BC1yokFH99xQP5ccGsEHmRdqBBB6-nKvQUFi75FWEgi0-DE7fZ8J3TVbaGtgb_BLY8TVOQXcjBt8K-A3PPzqQaFmu19Njr98O39Wei7N4RaRMkKl1xVsRZ1LS03qHaliucqs2jixYnBbxmrqDCZElWCBro0XMdKF1ZTJkAkaqPSB2yvaRt7wEBXGYI2XmuVIcZIqTLUcjKO2lClueEBi7brWGpf2pw6bMzKzsSRotwsfUnpbLT0ZRKw1_2Qxaaux2XEz4g5ys3R1B4TyhMupCwkqkABe9FRUEWNhlJ2JmrtXPnx65cB0StPVLf4eFr5ExAtLQn-vkt5OKDELa-Ht7dcWnrIceXfDRKw5_1tGklpdI1t10iDaEzSrcgC9nDD1P3bJzmquoIXAcsH7N4TUCHy4Z1m-r0rSM4lVXnDkUfbjbHzWP_-qEf93vn_Ejy6_JUfs_2E9jW5x5JDtrdaru0T1BZX1dMOEv4AY7NqGQ
  priority: 102
  providerName: ProQuest
– databaseName: Springer Nature OA Free Journals
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3di9NAEF_kBD8exG-jp44iCN4Fk3Sz2fh2FI9TOB_Uwr2FzWZTC21SmhbxP_TP8jdpGprDD3zJQzM7TTI7M7_ZmZ0V4pVKymgUB86XSZHjEqS-KcrYT0YqSUunTNq2Yzj_pM4m8uNFfNE1i-a9MPv5-1Crtw3sp-byMuVHCM99WNurMewuV--N1bhPGCQ60F3S8rfDBm7nsvHd8z6XKyP79OhNcX1TLc2P72Y-3_NAp7fFrQ460slW1nfEFVfdFdfOu-T4PfFzMge3hs9JIhgDBKhgSQCl1Aaw1XQGv7UCbb0wZPloayoc5xBouXIL4PEpF8XQ3PECWkMGbBy3P_YBIKeOulROQ7x0S80GNgazlHIYy3K2bt6RoWV_GpjP3rEA43q3lZPaRrZUlySPod1gkPMSUEOzCn9FvBK_mFkyALH3xeT0_dfxmd8d1OBbFURrSNfkoVVlqZ0sgLBGRiYmdojmwqjAtwxNkBaxUXmEWFwX0obGps5y0j9QZWFGD8RBVVfukSCbx7DPuJYmhjnR2sQANLEE8MmtLKQngp0cM9t1MefDNOZZG81olW1Fn3HlGos-izzxph-y3Lbw-Bvxc54c2XYXaq_-2YlUWqcaaMcTL1sKbp5RcXXO1GyaJvvw5fOA6HVHVNZ4PGu6zQ41iwS_71MeDiih3XZ4ezdLs866NFmoW2Q4CpUnXvS3eSRXzFWu3oAGhpcdWRp74uF2UvdvHyVAtUqmnkgG070n4J7jwzvV7Fvbe1xqbuiGkUc7xdh7rD9_1KNed_4tgsf_xfuJuBGxmvPCWHQoDtarjXsKnLjOn7UW4hcNxmKt
  priority: 102
  providerName: Springer Nature
– databaseName: Unpaywall
  dbid: UNPAY
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3ri9QwEA_HHvj44PtRPTWKIHh2r-2maeq3RTxP4Q5RF-4-lTRN9sp122W7RfQv9M9ypi-2iw8Ev5RlM0kfyfxmJvMIIc95YLyJ72ibBUkMFye0ZWJ8O5jwIDSay7Aux3B8wo9m7MOpf7pD3nW5MPECh1R6Nd5MP89qzIYf6uJgmZiG1QU_KAFdBQafcdsD490GLN7l6Gkakd3ZycfpWZ1bFLjoQwhan-Yv-w2k0jY2bwin7cDJ3nt6lVyu8qX89lVm2YaAOrxOzrtXa-JSLsbVOh6r71tVH__Du98g11ollk6bVXeT7Oj8Frl03Lrpb5MfswxGKvHEJgqwBKYyPD0F9ZjWpnQ-T0GCroC2WEiq8JBtmmj0ZtDlSi_AMphjeA7NNG7llVTCMBoLMdugys41bZ1KJcVNZFpWgHbALzQG2DbpunxNJV3255LZKKcTGLjokkppXVKXFoayV4AzMECMm1ElTXO4FUWfwCJVVII6fYfMDt9-eXNkt0dG2Io73hrWmYxdxY0RmiWg600kC6Svwa50vQQ-qCudMPEljz0eOiJhypUq1ArDDxxuEjm5S0Z5kev7hKrYB0kBVyN9ADYhpA-qlc9ABYsVS5hFnG7JRKqtp47HemRRbVcJHjUzFGEMHc5Q5FnkZd9l2RQT-RPxE1yHUZMP2wNRNGVciFCA3mWRZzUFlvHIMU5oLquyjN5__jQgetESmQIXkWzTLgqcEvh_k3JvQAk4o4bNHUNELc6VkStqHXXicos87ZuxJ8bu5bqogAZEAIrU0LfIvYZ_-rf3AtCvOQstEgw4qyfA6ufDljw9r6ugM4Gl5aDnfseDG4_1-4-637Pp36fgwT9RPyRXPORG3KLz9shovar0I9BY1_HjFo1-AhNhki8
  priority: 102
  providerName: Unpaywall
Title Ultrasound screening for cholangiocarcinoma could detect premalignant lesions and early-stage diseases with survival benefits: a population-based prospective study of 4,225 subjects in an endemic area
URI https://link.springer.com/article/10.1186/s12885-016-2390-2
https://www.ncbi.nlm.nih.gov/pubmed/27251649
https://www.proquest.com/docview/1800710316
https://www.proquest.com/docview/1793911195
https://pubmed.ncbi.nlm.nih.gov/PMC4890519
https://bmccancer.biomedcentral.com/track/pdf/10.1186/s12885-016-2390-2
UnpaywallVersion publishedVersion
Volume 16
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVADU
  databaseName: BioMed Central
  customDbUrl:
  eissn: 1471-2407
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017808
  issn: 1471-2407
  databaseCode: RBZ
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://www.biomedcentral.com/search/
  providerName: BioMedCentral
– providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1471-2407
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017808
  issn: 1471-2407
  databaseCode: KQ8
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1471-2407
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017808
  issn: 1471-2407
  databaseCode: DOA
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVEBS
  databaseName: EBSCOhost Academic Search Ultimate
  customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn
  eissn: 1471-2407
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017808
  issn: 1471-2407
  databaseCode: ABDBF
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn
  providerName: EBSCOhost
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1471-2407
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017808
  issn: 1471-2407
  databaseCode: DIK
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 1471-2407
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017808
  issn: 1471-2407
  databaseCode: GX1
  dateStart: 0
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 1471-2407
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017808
  issn: 1471-2407
  databaseCode: M~E
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 1471-2407
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017808
  issn: 1471-2407
  databaseCode: RPM
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 1471-2407
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017808
  issn: 1471-2407
  databaseCode: 7X7
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 1471-2407
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017808
  issn: 1471-2407
  databaseCode: BENPR
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVFZP
  databaseName: Scholars Portal Journals: Open Access
  customDbUrl:
  eissn: 1471-2407
  dateEnd: 20250930
  omitProxy: true
  ssIdentifier: ssj0017808
  issn: 1471-2407
  databaseCode: M48
  dateStart: 20010801
  isFulltext: true
  titleUrlDefault: http://journals.scholarsportal.info
  providerName: Scholars Portal
– providerCode: PRVAVX
  databaseName: Springer Nature HAS Fully OA
  customDbUrl:
  eissn: 1471-2407
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017808
  issn: 1471-2407
  databaseCode: AAJSJ
  dateStart: 20011201
  isFulltext: true
  titleUrlDefault: https://www.springernature.com
  providerName: Springer Nature
– providerCode: PRVAVX
  databaseName: Springer Nature OA Free Journals
  customDbUrl:
  eissn: 1471-2407
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017808
  issn: 1471-2407
  databaseCode: C6C
  dateStart: 20011201
  isFulltext: true
  titleUrlDefault: http://www.springeropen.com/
  providerName: Springer Nature
– providerCode: PRVAVX
  databaseName: SpringerLink Journals (ICM)
  customDbUrl:
  eissn: 1471-2407
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017808
  issn: 1471-2407
  databaseCode: U2A
  dateStart: 20011201
  isFulltext: true
  titleUrlDefault: http://www.springerlink.com/journals/
  providerName: Springer Nature
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1tb9MwELbGKvHyAfFOYRSDkJAYgSZ1HAcJoa7aNJBaTYNIhS-RkzilUpuUphXsH_KzeC5NQzuNly-WGp-d1D4_d_ad7xh7Jr3U6bhtYwkviVC0fUsnqWt5Hen5qZHaL8Mx9AfyOBAfhu5wh63TW1UDWFy4taN8UsF88urHt7N3WPBvywWv5OsCGKvIBU1aDrbwFhC5AcHkEJP3xW-jgqfKBHU28JiMCl5l5Lywiy0xdR6sN6TVeU_K2px6jV1ZZjN99l1PJhsS6-gGu16pmry74o2bbMdkt9jlfmVMv81-BhP0VlBeJQ7wwIYWXXIosbwclWw0hpybgzafah5TKmyeGLI58NncTKG_j8iJhk8MHbgVXKMbQ-GSLSicI8Mr00_B6aiXF0tgEriaRwDXdLwo3nDNZ3X2MIukaYKO8_XVT14GvuV5ysVLoAE6iOjIqODjDK_idHI_HcdcQ-m9w4Kjw0-9Y6tK7GDFsu0swA06smOZpsqIBBpZRwtPuwa7P9tJMJa2bvuJq2XkYO-uEhHbOvZNTE4CbZkmunOX7WZ5Zu4zHkcu8Bxlql3Aj1LahQLkCihKUSwS0WTt9TyGcRX1nJJvTMJy96NkuJr6kDzdaOpDp8le1E1mq5AffyN-TMwRrm6t1nARdoVUylfQjprsaUlBwTYy8uYZ6WVRhO8_nm4RPa-I0hyfF-vqckROU4Lnm5R7W5RAg3i7es2l4XoxhbYqNcmOLZvsSV1NLcnDLjP5EjQAahJ8vttk91ZMXf97x4MWLIXfZN4Wu9cEFKN8uyYbfy1jlQtFAeDQcn-9MDY-68-Dul-vnX9PwYP_HruH7KpDS5wO0Zw9truYL80j6JSLqMUueUOvxRoHh4OTU_zqyV6rPJ9plRiC8vTgC8rAwZNGMDjpfv4Ff-x7MQ
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfGkBg8IL4JDGYQCGkjWj4cx0FCaAKmlq17gFXqW3Bsp1Rqk9K0mvZP8XfwZ3GXL5pJjKe95KE-u07O_t2d73xHyCsepp4fOMZmoU7g4US21Glghz4Po9RwGZXpGAYnvDdkX0bBaIP8au7CYFhlg4klUOtc4Rn5vitKaei7_MP8p41Vo9C72pTQqJbFkTk_A5OteN__BPx97XmHn08_9uy6qoCtuOMtYSoycRVPU2GYBnXAlyyUgQHTw_W0VsaVTqQDyRMPDEehmXKlioxCD7XDUy19GPcauc58h2Gu_nDUGnhuKBxRe05dwfcLwH6BoXHc9vzIsb2O7LsoAdZE4MXwzNZHe4tsrbK5PD-T0-maGDy8Q27X-is9qBbcXbJhsnvkxqD20N8nv4dTGK3AYk0UEAmsZBiSgmZMSys6G09AeC6ANp9JqrC-NtUGHRl0vjAzMArGGJlDpwZP8QoqYRiDOZht0GLHhtb-pILi-TEtVgB0sFVoAoidTpbFOyrpvC1JZqOI1jBw3twnpWU2XZqnlL0FiIEBEjyHKugkg7-i6A6YTRSVoEk_IMMr4etDspnlmXlMqEoCEBLwTGUAmCaEDECrChhoX4limlnEafgYqzqVOlb0mMalSSV4XLE-xvA5ZH3sWWS37TKv8ohcRryDiyOursK2GBQfMC5EJEDlssjLkgIzeGQYIjSWq6KI-9--doje1ERpDtNTsr5xkSNL4Pd1yu0OJUCM6jY3qzSuIa6I_25Ii7xom7Enhu1lJl8BDaA_StMosMijalG3b--FoFpzFlkk7Cz3lgATn3dbssmPMgE6E5hVDnruNRtjbVr__qh77d75PwueXP7KO2Srdzo4jo_7J0dPyU0P9zgezXnbZHO5WJlnoKkuk-clPFDy_arx6A8jD6hr
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR1db9Mw0EKbNOAB8U3GYAYhITGiJanjOLxVQLUVNiFGpb1ZjmN3ldqkaloh_iE_i7vEiZqJD_GSh-Z8TXLfvvMdIa94YqNBHBifJXkGlyD1VW5jPxnwJLWGq7Rux3B2zk8mbHwZX7o5p1Vb7d6mJJszDdilqVgfL3PbiLjgxxVoVYFFZ9yPIGj3QQfvijjlEH3tDofji3GXSEhEIFwy87cLe-boulLeskrXKya7tOltcnNTLNWP72o-37JMo7vkjnMp6bDhgXvkhinuk70zlzR_QH5O5oCtwvlJFJQEBK6AkoKzSuvAtpjOwJ6tALZcKKpx5DXNDeYW6HJlFuCnT7FYhs4NbqxVVAEag22RfXAsp4a6FE9FcUuXVhvQPcC9NAMlamfr6h1VdNlNCfPRauaAuGyPeNK6wS0tLWVvQeoBQYZbQxWdFfBXFHfoFzNNFTi3D8lk9PHb-xPfDXDwNQ-iNVBdZaHm1grDcvC8BoolKjYQ5YVRDt8yVEGax4pnEcToImc6VDo1GosBAm5zNXhEdoqyME8I1VkMehuuVsWgZoRQMTg6MQOHKNMsZx4JWjpK7bqb45CNuayjHMFlQ3qJFW1Iehl55E23ZNm09vgb8CEyh2xOp3ZqQQ4ZFyIV4AV55GUNgU01CqzamapNVcnTi689oNcOyJbweFq5QxAlkgR-34Y86EGC1Ov-7ZZLpdM6lQxF7TEOQu6RF91tXImVdIUpNwADChkNXBp75HHD1N3bRwl4u5ylHkl67N4BYC_y_p1idlX3JGcCG73ByqNWMLYe688f9aiTnX-TYP-_cB-SvS8fRvLz6fmnp-RWhBKPe2fRAdlZrzbmGbiS6-y5Uxe_ADcBb1g
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3ri9QwEA_HHvj44PtRPTWKIHh2r-2maeq3RTxP4Q5RF-4-lTRN9sp122W7RfQv9M9ypi-2iw8Ev5RlM0kfyfxmJvMIIc95YLyJ72ibBUkMFye0ZWJ8O5jwIDSay7Aux3B8wo9m7MOpf7pD3nW5MPECh1R6Nd5MP89qzIYf6uJgmZiG1QU_KAFdBQafcdsD490GLN7l6Gkakd3ZycfpWZ1bFLjoQwhan-Yv-w2k0jY2bwin7cDJ3nt6lVyu8qX89lVm2YaAOrxOzrtXa-JSLsbVOh6r71tVH__Du98g11ollk6bVXeT7Oj8Frl03Lrpb5MfswxGKvHEJgqwBKYyPD0F9ZjWpnQ-T0GCroC2WEiq8JBtmmj0ZtDlSi_AMphjeA7NNG7llVTCMBoLMdugys41bZ1KJcVNZFpWgHbALzQG2DbpunxNJV3255LZKKcTGLjokkppXVKXFoayV4AzMECMm1ElTXO4FUWfwCJVVII6fYfMDt9-eXNkt0dG2Io73hrWmYxdxY0RmiWg600kC6Svwa50vQQ-qCudMPEljz0eOiJhypUq1ArDDxxuEjm5S0Z5kev7hKrYB0kBVyN9ADYhpA-qlc9ABYsVS5hFnG7JRKqtp47HemRRbVcJHjUzFGEMHc5Q5FnkZd9l2RQT-RPxE1yHUZMP2wNRNGVciFCA3mWRZzUFlvHIMU5oLquyjN5__jQgetESmQIXkWzTLgqcEvh_k3JvQAk4o4bNHUNELc6VkStqHXXicos87ZuxJ8bu5bqogAZEAIrU0LfIvYZ_-rf3AtCvOQstEgw4qyfA6ufDljw9r6ugM4Gl5aDnfseDG4_1-4-637Pp36fgwT9RPyRXPORG3KLz9shovar0I9BY1_HjFo1-AhNhki8
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Ultrasound+screening+for+cholangiocarcinoma+could+detect+premalignant+lesions+and+early-stage+diseases+with+survival+benefits%3A+a+population-based+prospective+study+of+4%2C225+subjects+in+an+endemic+area&rft.jtitle=BMC+cancer&rft.au=Sungkasubun%2C+Prakongboon&rft.au=Siripongsakun%2C+Surachate&rft.au=Akkarachinorate%2C+Kunlayanee&rft.au=Vidhyarkorn%2C+Sirachat&rft.date=2016-06-02&rft.pub=BioMed+Central+Ltd&rft.issn=1471-2407&rft.eissn=1471-2407&rft.volume=16&rft.issue=1&rft_id=info:doi/10.1186%2Fs12885-016-2390-2&rft.externalDocID=A468898152
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2407&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2407&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2407&client=summon